Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking …

iobenguane
vincristine
melphalan
catecholamines
conventional surgery
  • 117 views
  • 15 Oct, 2022
  • 105 locations
Precision Dosing of Busulfan in Children Undergoing HSCT

HSCT efficacy while reducing conditioning-related toxicities. Namely, we are going to compare the accuracy of two methods for determining the first dose of busulfan, one of the medicines used during

  • 0 views
  • 11 Aug, 2021
  • 1 location
Targeted Busulfan Fludarabine Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.

To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan, fludarabine, etoposide conditioning regimen in childhood and adolescent ALL.

cell transplantation
ejection fraction
transplant conditioning
busulfan
fludarabine
  • 14 views
  • 26 Jun, 2021
  • 1 location
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

failure. Different technologies of with replete or depleted graft are associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most commonly used approach for a variety of

myeloablative conditioning
fludarabine
busulfan
mycophenolate mofetil
tacrolimus
  • 0 views
  • 04 Oct, 2022
  • 1 location
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

cladribine
KRAS
gilbert's syndrome
fludarabine
blast cells
  • 0 views
  • 28 Oct, 2022
  • 1 location
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral

  • 26 views
  • 04 Oct, 2022
  • 5 locations
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1) test the …

bone marrow transplant
KRAS
fludarabine
chronic myelomonocytic leukemia
TP53
  • 34 views
  • 04 Oct, 2022
  • 1 location
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond

refractory acute myeloid leukemia (aml)
ejection fraction
fludarabine
busulfan
mycophenolate mofetil
  • 13 views
  • 04 Oct, 2022
  • 1 location
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as

myeloproliferative disorder
melphalan
fludarabine
chronic myelomonocytic leukemia
acute leukemia
  • 5 views
  • 27 Oct, 2022
  • 1 location
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

leukodystrophy
treatment regimen
gm1 gangliosidosis
sandhoff disease
mucopolysaccharidosis
  • 267 views
  • 12 Nov, 2021
  • 1 location